149 related articles for article (PubMed ID: 37521829)
1. Clonal heterogeneity by fluorescence in situ hybridization in multiple myeloma: enhanced cytogenetic risk stratification.
Abdel-Qader HY; Fouad DA; Abuelela SA; Ismail HMA; Boshnaq NH
Egypt J Med Hum Genet; 2022; 23(1):66. PubMed ID: 37521829
[TBL] [Abstract][Full Text] [Related]
2. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
3. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetics and Revised International Staging System (R-ISS): Risk Stratification in Multiple myeloma - A Retrospective Study in Indian Population.
Udupa CBK; Udupa KS; Pai A; Sherigar P
Iran J Pathol; 2020; 15(3):182-188. PubMed ID: 32754213
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
[TBL] [Abstract][Full Text] [Related]
6. A diagnostic approach to detect cytogenetic heterogeneity and its prognostic significance in multiple myeloma.
Kalal AA; Arumugam M; Shetty VV; Shetty KP; Krishna R; Shetty RA; Kulkarni NV; Shetty DP
J Taibah Univ Med Sci; 2023 Oct; 18(5):1138-1147. PubMed ID: 37206191
[TBL] [Abstract][Full Text] [Related]
7. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients.
Hamdaoui H; Benlarroubia O; Ait Boujmia OK; Mossafa H; Ouldim K; Belkhayat A; Smyej I; Benrahma H; Dehbi H; Chegdani F
Mol Genet Genomic Med; 2020 Sep; 8(9):e1363. PubMed ID: 32573970
[TBL] [Abstract][Full Text] [Related]
9. [Cytogenetic abnormalities and morphological changes of bone marrow in multiple myeloma: a pathological analysis of 151 cases].
Chen H; Zeng BB; Zhao Y; Xie Y; Jin ML
Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1136-1141. PubMed ID: 33152818
[No Abstract] [Full Text] [Related]
10. Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells.
Kishimoto RK; de Freitas SL; Ratis CA; Borri D; Sitnik R; Velloso ED
Rev Bras Hematol Hemoter; 2016; 38(2):113-20. PubMed ID: 27208569
[TBL] [Abstract][Full Text] [Related]
11. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
12. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic Abnormalities in Multiple Myeloma: Incidence, Prognostic Significance, and Geographic Heterogeneity in Indian and Western Populations.
Kadam Amare P; Nikalje Khasnis S; Hande P; Lele H; Wable N; Kaskar S; Nikam Gujar N; Gardi N; Prabhudesai A; Todi K; Waghole R; Roy P
Cytogenet Genome Res; 2022; 162(10):529-540. PubMed ID: 36780889
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.
Schmidt-Hieber M; Gutiérrez ML; Pérez-Andrés M; Paiva B; Rasillo A; Tabernero MD; Sayagués JM; Lopez A; Bárcena P; Sanchez ML; Gutiérrez NC; San Miguel JF; Orfao A
Haematologica; 2013 Feb; 98(2):279-87. PubMed ID: 22929983
[TBL] [Abstract][Full Text] [Related]
15. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.
Avet-Loiseau H; Durie BG; Cavo M; Attal M; Gutierrez N; Haessler J; Goldschmidt H; Hajek R; Lee JH; Sezer O; Barlogie B; Crowley J; Fonseca R; Testoni N; Ross F; Rajkumar SV; Sonneveld P; Lahuerta J; Moreau P; Morgan G;
Leukemia; 2013 Mar; 27(3):711-7. PubMed ID: 23032723
[TBL] [Abstract][Full Text] [Related]
16. [High risk cytogenetic abnormalities in patients with multiple myeloma].
Legües ME; Morales P; Valenzuela M; Encina A; Martí MJ; Bascuñán C; Cornejo P; Peña C; Undurraga MS
Rev Med Chil; 2019; 147(1):61-64. PubMed ID: 30848766
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China.
Mei J; Zhai Y; Li H; Li F; Zhou X; Song P; Zhao Q; Yu Y; An Z; Wang L
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2263-2273. PubMed ID: 30167888
[TBL] [Abstract][Full Text] [Related]
18. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
[TBL] [Abstract][Full Text] [Related]
20. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.
Mellors PW; Binder M; Ketterling RP; Greipp PT; Baughn LB; Peterson JF; Jevremovic D; Pearce KE; Buadi FK; Lacy MQ; Gertz MA; Dispenzieri A; Hayman SR; Kapoor P; Gonsalves WI; Hwa YL; Fonder A; Hobbs M; Kourelis T; Warsame R; Lust JA; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2020 May; 4(10):2236-2244. PubMed ID: 32442300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
